A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors

Authors:
  • SIS. Isakoff
    S. Isakoff
  • RBR. Bahleda
    R. Bahleda
  • MSM. Saleh
    M. Saleh
  • RBR. Bordoni
    R. Bordoni
  • ASA. Shields
    A. Shields
  • JDJ. Dauer
    J. Dauer
  • MCM. Curley
    M. Curley
  • JBJ. Baum
    J. Baum
  • TMT. McClure
    T. McClure
  • CLC.U. Louis
    C.U. Louis
  • JSJ.C. Soria
    J.C. Soria

Abstract
No abstract available